Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 8:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,201 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Blinded (placebo) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers

NCT02062203
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AKB-6548 (therapeutic dose), AKB-6548 (supratherapeutic dose), Placebo, Moxifloxacin
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With Suvorexant

NCT05733286
View directory record Official record
Conditions
Delirium in Old Age
Interventions
Suvorexant 20 mg, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety Study of Iontophoretic Application of Terbinafine Gel in Subjects With Onychomycosis

NCT01080079
View directory record Official record
Conditions
Onychomycosis
Interventions
Terbinafine Hydrochloride, Purified Water
Drug · Other
Lead sponsor
Nitric BioTherapeutics, Inc
Industry
Eligibility
18 Years to 69 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
7
States / cities
Birmingham, Alabama • Sanford, Florida • Snellville, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2012 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 3 Interventional Results available

Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections

NCT00466817
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Placebo, Valganciclovir
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 30 Days
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Sep 24, 2026, 8:21 AM EDT
Active, not recruiting Phase 1 Interventional

A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)

NCT06436742
View directory record Official record
Conditions
Congenital Myasthenic Syndrome, CMS
Interventions
ARGX-119, Placebo
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Sacramento, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Light Therapy for Depression in Adolescent Outpatients

NCT05823090
View directory record Official record
Conditions
Depression, Adolescent - Emotional Problem
Interventions
light box (Carex DayLight Classic Model)
Device
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Epsilon Aminocaproic Acid (EACA) for the Reduction of Blood Loss in Total Hip Arthroplasty (THA)

NCT01391182
View directory record Official record
Conditions
Degenerative Joint Disease, Osteoarthritis
Interventions
EACA, Placebo arm
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 2 Interventional Results available

A Trial of Lipitor (Atorvastatin) for the Treatment of Polycystic Ovary Syndrome (PCOS) in Women With Elevated Low-density Lipoprotein (LDL) Cholesterol

NCT00529542
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Lipitor, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Treatment of Asian Flushing Syndrome With Topical Alpha Agonists

NCT03497442
View directory record Official record
Conditions
Flushing, Alcohol-Related Disorders, Aldehyde Dehydrogenase Deficiency
Interventions
Brimonidine Tartrate, Placebo Vehicle Gel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 3, 2020 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects

NCT01454986
View directory record Official record
Conditions
Healthy
Interventions
ALXN1007, Placebo
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
25 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers

NCT01931059
View directory record Official record
Conditions
Imaging of the Brain and Antipsychotics, Neuronal Network Changes
Interventions
Risperidone, Placebo
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2018 · Synced Sep 24, 2026, 8:21 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Once Versus Twice Daily Iron Supplementation in Pregnant Women

NCT02839096
View directory record Official record
Conditions
Anemia in Pregnancy
Interventions
Placebo, Ferrous Sulfate
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 3 Interventional Results available

A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

NCT01602380
View directory record Official record
Conditions
Hormone Receptor Positive Breast Cancer
Interventions
faslodex 500mg, arimidex 1mg, faslodex dummy, arimidex dummy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
12
States / cities
Modesto, California • Savannah, Georgia • Auburn, Maine + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 4 Interventional

Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease

NCT03667703
View directory record Official record
Conditions
Congenital Heart Disease, Upper Gastrointestinal Bleeding, Stress Ulcer, Infection
Interventions
Famotidine, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Minute to 12 Months
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Sep 24, 2026, 8:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Rapid Effects of a Biofield Patch on Antioxidant Status and Cellular Energy

NCT07314359
View directory record Official record
Conditions
Antioxidant Status
Interventions
Active dermal patch, Placebo dermal patch
Other
Lead sponsor
Natural Immune Systems Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Klamath Falls, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects

NCT02807207
View directory record Official record
Conditions
Healthy Subjects
Interventions
A: pacritinib, B: Placebo, C: moxifloxacin
Drug · Other
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Sep 24, 2026, 8:21 AM EDT
Recruiting Phase 1 Interventional

Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)

NCT07559500
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
Tirzepatide, Placebo, [11C]raclopride plus drug, [11C]NNC-112
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 24, 2026, 8:21 AM EDT
Terminated Early Phase 1 Interventional Results available

Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas

NCT01147601
View directory record Official record
Conditions
Hemangioma, Infant
Interventions
topical 0.5% Timolol, Control (placebo) group
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
1 Month to 8 Months
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 4, 2017 · Synced Sep 24, 2026, 8:21 AM EDT
Not listed Phase 1Phase 2 Interventional

Safety Evaluation of Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis

NCT05006430
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Fecal Microbiota Transplantation, Placebo
Biological · Other
Lead sponsor
Prasun Kumar Jalal
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Texas 2017 (H3N2) Challenge Study

NCT06476275
View directory record Official record
Conditions
Influenza Viral Infections
Interventions
Influenza A/Texas/71/2017 (H3N2), Sham placebo
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years to 46 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Trial of a Nicotinic Agonist in Schizophrenia

NCT00100165
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, 3-(2,4 dimethoxybenzylidene anabaseine) 150 mg, 3-(2,4 dimethoxybenzylidene anabaseine) 75 mg
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 3 Interventional Results available

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

NCT02471144
View directory record Official record
Conditions
Chronic Severe Plaque-type Psoriasis
Interventions
Experimental : Secukinumab low dose, Experimental: Secukinumab high dose, Placebo Comparator: Secukinumab Placebo, Active Comparator: Etanercept
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 24, 2026, 8:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Role of Intra-Operative Intracapsular Blocks in Post-Operative Pain Management Following Total Knee Arthroplasty

NCT00620828
View directory record Official record
Conditions
Osteoarthritis
Interventions
Placebo saline injection, Ropivicaine 0.5%
Other · Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 24, 2026, 8:21 AM EDT
Withdrawn Phase 4 Interventional

A Trial of Pulse Dyed Laser (Chromogenex Regenlite Transform) in the Treatment of Inflammatory Acne Vulgaris

NCT02647528
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Chromogenix Regenlite Transform Treatment, Chromogenix Regenlite Transform Placebo
Device
Lead sponsor
Sadick Research Group
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Sep 24, 2026, 8:21 AM EDT